Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

Antibody–drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood–brain tumor barrier. Trastuzumab deruxtecan (T-DXd), a high-payload antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Moss, Nelson S, Tosi, Umberto, Santomasso, Bianca D, Beal, Kathryn, Modi, Shanu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280405/
https://www.ncbi.nlm.nih.gov/pubmed/35674041
http://dx.doi.org/10.2217/cns-2022-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280405/
https://www.ncbi.nlm.nih.gov/pubmed/35674041
http://dx.doi.org/10.2217/cns-2022-0010

Ejemplares similares